163 related articles for article (PubMed ID: 38063787)
1. Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy.
Carbonell D; Monsalvo S; Catalá E; Pérez-Corral A; Villegas C; Falero C; Ruano G; Martinez M; Kwon M; Muñoz-Martínez C; Díez-Martín JL; Gayoso J; Anguita J
Blood Transfus; 2024 May; 22(3):239-245. PubMed ID: 38063787
[TBL] [Abstract][Full Text] [Related]
2. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
Tyagarajan S; Schmitt D; Acker C; Rutjens E
Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
[TBL] [Abstract][Full Text] [Related]
3. Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL.
Korell F; Laier S; Sauer S; Veelken K; Hennemann H; Schubert ML; Sauer T; Pavel P; Mueller-Tidow C; Dreger P; Schmitt M; Schmitt A
Cells; 2020 May; 9(5):. PubMed ID: 32429189
[TBL] [Abstract][Full Text] [Related]
4. Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.
Qayed M; McGuirk JP; Myers GD; Parameswaran V; Waller EK; Holman P; Rodrigues M; Clough LF; Willert J
Cytotherapy; 2022 Sep; 24(9):869-878. PubMed ID: 35718701
[TBL] [Abstract][Full Text] [Related]
5. Leukapheresis for CAR-T cell production and therapy.
Pessach I; Nagler A
Transfus Apher Sci; 2023 Dec; 62(6):103828. PubMed ID: 37838564
[TBL] [Abstract][Full Text] [Related]
6. Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients.
Jarisch A; Rettinger E; Sörensen J; Klingebiel T; Schäfer R; Seifried E; Bader P; Bonig H
J Clin Apher; 2020 Sep; 35(5):398-405. PubMed ID: 32750197
[TBL] [Abstract][Full Text] [Related]
7. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
Palen K; Zurko J; Johnson BD; Hari P; Shah NN
Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
[TBL] [Abstract][Full Text] [Related]
8. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
Teoh J; Brown LF
Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
[TBL] [Abstract][Full Text] [Related]
9. Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.
Schultz L; Patel S; Davis KL; Ramakrishna S; Sahaf B; Bhatia N; Baggott C; Erickson C; Majzner RG; Oak J; Bertaina A; Mackall C; Feldman S
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929049
[TBL] [Abstract][Full Text] [Related]
10. Managing leukapheresis in adult and pediatric patients eligible for chimeric antigen receptor T-cell therapy: suggestions from an Italian Expert Panel.
Leone G; Baldini V; Bramanti S; Crocchiolo R; Gattillo S; Ermini S; Giudice V; Ferrero I; Moscato T; Milani R; Gozzer M; Piccirillo N; Tassi C; Tassi V; Coluccia P
Blood Transfus; 2023 Nov; 21(6):514-525. PubMed ID: 37146295
[TBL] [Abstract][Full Text] [Related]
11. The role of cryopreservation techniques in manufacturing, transport, and storage of Car-T therapy products.
Jandova M; Stacey GN; Lanska M; Gregor I; Rozsivalova P; Bekova L; Duchacova ZW; Belada D; Radocha J; Mericka P; Fuller B
Cryo Letters; 2023; 44(3):123-133. PubMed ID: 37883165
[TBL] [Abstract][Full Text] [Related]
12. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control.
Cai Y; Prochazkova M; Jiang C; Song HW; Jin J; Moses L; Gkitsas N; Somerville RP; Highfill SL; Panch S; Stroncek DF; Jin P
J Transl Med; 2021 Dec; 19(1):523. PubMed ID: 34952597
[TBL] [Abstract][Full Text] [Related]
13. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
[TBL] [Abstract][Full Text] [Related]
15. A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy.
Jo T; Yoshihara S; Hada A; Arai Y; Kitawaki T; Ikemoto J; Onomoto H; Sugiyama H; Yoshihara K; Obi N; Matsui K; Niwa N; Nakagawa Y; Kanda J; Kondo T; Saida S; Kato I; Hiramatsu H; Adachi S; Takita J; Takaori-Kondo A; Nagao M
Transplant Cell Ther; 2022 Jul; 28(7):365.e1-365.e7. PubMed ID: 35460928
[TBL] [Abstract][Full Text] [Related]
16. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Roddie C; Dias J; O'Reilly MA; Abbasian M; Cadinanos-Garai A; Vispute K; Bosshard-Carter L; Mitsikakou M; Mehra V; Roddy H; Hartley JA; Spanswick V; Lowe H; Popova B; Clifton-Hadley L; Wheeler G; Olejnik J; Bloor A; Irvine D; Wood L; Marzolini MAV; Domning S; Farzaneh F; Lowdell MW; Linch DC; Pule MA; Peggs KS
J Clin Oncol; 2021 Oct; 39(30):3352-3363. PubMed ID: 34464155
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Badar T; Shah NN
Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
[TBL] [Abstract][Full Text] [Related]
18. Leukapheresis and Tisagenlecleucel Manufacturing Outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Fong D; Tiwari R; Acker C; Clough L; Willert J
Transplant Cell Ther; 2023 Sep; 29(9):579.e1-579.e10. PubMed ID: 37311511
[TBL] [Abstract][Full Text] [Related]
19. CD4
Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
[TBL] [Abstract][Full Text] [Related]
20. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]